Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
Abstract The efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell therapy (CAR-T) progression/failure is unknown. Hence, we sought to examine real-world use and outcomes of lonca following CAR-T in patients with relapsed or refractory (R/R) diffuse large B-cell lymph...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-11-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-024-01195-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850216578002452480 |
|---|---|
| author | Narendranath Epperla Melanie Lucero Tom Bailey Laura Mirams Jolenta Cheung Mona Amet Gary Milligan Lei Chen |
| author_facet | Narendranath Epperla Melanie Lucero Tom Bailey Laura Mirams Jolenta Cheung Mona Amet Gary Milligan Lei Chen |
| author_sort | Narendranath Epperla |
| collection | DOAJ |
| description | Abstract The efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell therapy (CAR-T) progression/failure is unknown. Hence, we sought to examine real-world use and outcomes of lonca following CAR-T in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the USA. In this retrospective study, we included adults (age ≥ 18 years) with R/R DLBCL who received lonca monotherapy as third- (3 L) or fourth line (4 L) treatment after progressing on second line (2 L) or 3 L CAR-T, respectively. Post-CAR-T lonca outcomes included response rates (overall response rate [ORR] and complete response [CR] rate), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). A total of 118 patients were included in the analysis with 95 receiving lonca following 2 L CAR-T (median age:66 years; 61% male) and 23 following 3 L CAR-T (median age:57 years; 43% male). Patients with 2 L CAR-T/3 L lonca had an ORR of 73% (CR rate of 34%). With a median follow-up of 8.5 months following lonca initiation, median DOR, PFS, and OS were not reached. The DOR, PFS, and OS at 12 months were 68%, 77%, and 84%, respectively. Patients with 3 L CAR-T/4 L lonca had an ORR of 78% (CR rate of 17%). With a median follow-up of 13 months following lonca initiation, the median DOR and PFS were 7.6 and 12.0 months, while median OS was not reached. OS at 12 months was 95%. In this study, we found that lonca monotherapy was an effective treatment option in R/R DLBCL in 3 L and 4 L settings including those who were resistant to or progressed after CAR-T. |
| format | Article |
| id | doaj-art-e2bba572381f4cf38a69971002c52dd8 |
| institution | OA Journals |
| issn | 2044-5385 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj-art-e2bba572381f4cf38a69971002c52dd82025-08-20T02:08:15ZengNature Publishing GroupBlood Cancer Journal2044-53852024-11-011411710.1038/s41408-024-01195-4Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphomaNarendranath Epperla0Melanie Lucero1Tom Bailey2Laura Mirams3Jolenta Cheung4Mona Amet5Gary Milligan6Lei Chen7Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of UtahADC TherapeuticsAdelphi Real WorldAdelphi Real WorldAdelphi Real WorldAdelphi Real WorldAdelphi Real WorldADC TherapeuticsAbstract The efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell therapy (CAR-T) progression/failure is unknown. Hence, we sought to examine real-world use and outcomes of lonca following CAR-T in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the USA. In this retrospective study, we included adults (age ≥ 18 years) with R/R DLBCL who received lonca monotherapy as third- (3 L) or fourth line (4 L) treatment after progressing on second line (2 L) or 3 L CAR-T, respectively. Post-CAR-T lonca outcomes included response rates (overall response rate [ORR] and complete response [CR] rate), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). A total of 118 patients were included in the analysis with 95 receiving lonca following 2 L CAR-T (median age:66 years; 61% male) and 23 following 3 L CAR-T (median age:57 years; 43% male). Patients with 2 L CAR-T/3 L lonca had an ORR of 73% (CR rate of 34%). With a median follow-up of 8.5 months following lonca initiation, median DOR, PFS, and OS were not reached. The DOR, PFS, and OS at 12 months were 68%, 77%, and 84%, respectively. Patients with 3 L CAR-T/4 L lonca had an ORR of 78% (CR rate of 17%). With a median follow-up of 13 months following lonca initiation, the median DOR and PFS were 7.6 and 12.0 months, while median OS was not reached. OS at 12 months was 95%. In this study, we found that lonca monotherapy was an effective treatment option in R/R DLBCL in 3 L and 4 L settings including those who were resistant to or progressed after CAR-T.https://doi.org/10.1038/s41408-024-01195-4 |
| spellingShingle | Narendranath Epperla Melanie Lucero Tom Bailey Laura Mirams Jolenta Cheung Mona Amet Gary Milligan Lei Chen Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma Blood Cancer Journal |
| title | Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma |
| title_full | Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma |
| title_fullStr | Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma |
| title_full_unstemmed | Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma |
| title_short | Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma |
| title_sort | outcomes with loncastuximab tesirine following car t cell therapy in patients with relapsed or refractory diffuse large b cell lymphoma |
| url | https://doi.org/10.1038/s41408-024-01195-4 |
| work_keys_str_mv | AT narendranathepperla outcomeswithloncastuximabtesirinefollowingcartcelltherapyinpatientswithrelapsedorrefractorydiffuselargebcelllymphoma AT melanielucero outcomeswithloncastuximabtesirinefollowingcartcelltherapyinpatientswithrelapsedorrefractorydiffuselargebcelllymphoma AT tombailey outcomeswithloncastuximabtesirinefollowingcartcelltherapyinpatientswithrelapsedorrefractorydiffuselargebcelllymphoma AT lauramirams outcomeswithloncastuximabtesirinefollowingcartcelltherapyinpatientswithrelapsedorrefractorydiffuselargebcelllymphoma AT jolentacheung outcomeswithloncastuximabtesirinefollowingcartcelltherapyinpatientswithrelapsedorrefractorydiffuselargebcelllymphoma AT monaamet outcomeswithloncastuximabtesirinefollowingcartcelltherapyinpatientswithrelapsedorrefractorydiffuselargebcelllymphoma AT garymilligan outcomeswithloncastuximabtesirinefollowingcartcelltherapyinpatientswithrelapsedorrefractorydiffuselargebcelllymphoma AT leichen outcomeswithloncastuximabtesirinefollowingcartcelltherapyinpatientswithrelapsedorrefractorydiffuselargebcelllymphoma |